Plasma Protease C1-inhibitor Treatment Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL PLASMA PROTEASE C1-INHIBITOR TREATMENT INDUSTRY

2.1 Summary about Plasma Protease C1-inhibitor Treatment Industry

2.2 Plasma Protease C1-inhibitor Treatment Market Trends

2.2.1 Plasma Protease C1-inhibitor Treatment Production & Consumption Trends

2.2.2 Plasma Protease C1-inhibitor Treatment Demand Structure Trends

2.3 Plasma Protease C1-inhibitor Treatment Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 C1-inhibitors

4.2.2 Kallikrein Inhibitor (Kalbitor)

4.2.3 Selective Bradykinin B2 Receptor Antagonist (Firazyr)

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Hospital Pharmacies

4.3.2 Independent Pharmacies and Outlets

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 C1-inhibitors

5.2.2 Kallikrein Inhibitor (Kalbitor)

5.2.3 Selective Bradykinin B2 Receptor Antagonist (Firazyr)

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Hospital Pharmacies

5.3.2 Independent Pharmacies and Outlets

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 C1-inhibitors

6.2.2 Kallikrein Inhibitor (Kalbitor)

6.2.3 Selective Bradykinin B2 Receptor Antagonist (Firazyr)

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 Hospital Pharmacies

6.3.2 Independent Pharmacies and Outlets

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 C1-inhibitors

7.2.2 Kallikrein Inhibitor (Kalbitor)

7.2.3 Selective Bradykinin B2 Receptor Antagonist (Firazyr)

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Hospital Pharmacies

7.3.2 Independent Pharmacies and Outlets

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 C1-inhibitors

8.2.2 Kallikrein Inhibitor (Kalbitor)

8.2.3 Selective Bradykinin B2 Receptor Antagonist (Firazyr)

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Hospital Pharmacies

8.3.2 Independent Pharmacies and Outlets

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 C1-inhibitors

9.2.2 Kallikrein Inhibitor (Kalbitor)

9.2.3 Selective Bradykinin B2 Receptor Antagonist (Firazyr)

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Hospital Pharmacies

9.3.2 Independent Pharmacies and Outlets

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 Shire plc

10.1.2 CSL Limited

10.1.3 Sanquin

10.1.4 Pharming Group N.V.

10.2 Plasma Protease C1-inhibitor Treatment Sales Date of Major Players (2017-2020e)

10.2.1 Shire plc

10.2.2 CSL Limited

10.2.3 Sanquin

10.2.4 Pharming Group N.V.

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

Table Plasma Protease C1-inhibitor Treatment Product Type Overview

Table Plasma Protease C1-inhibitor Treatment Product Type Market Share List

Table Plasma Protease C1-inhibitor Treatment Product Type of Major Players

Table Brief Introduction of Shire plc

Table Brief Introduction of CSL Limited

Table Brief Introduction of Sanquin

Table Brief Introduction of Pharming Group N.V.

Table Products & Services of Shire plc

Table Products & Services of CSL Limited

Table Products & Services of Sanquin

Table Products & Services of Pharming Group N.V.

Table Market Distribution of Major Players

Table Global Major Players Sales Revenue (Million USD) 2017-2020e

Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

Table Global Plasma Protease C1-inhibitor Treatment Market Forecast (Million USD) by Region 2021f-2026f

Table Global Plasma Protease C1-inhibitor Treatment Market Forecast (Million USD) Share by Region 2021f-2026f

Table Global Plasma Protease C1-inhibitor Treatment Market Forecast (Million USD) by Demand 2021f-2026f

Table Global Plasma Protease C1-inhibitor Treatment Market Forecast (Million USD) Share by Demand 2021f-2026f